RePORT International Resources

Can assess all the 13th IAS Conference on HIV Science at this website

The Antibacterial Resistance Leadership Group (ARLG) invites requests for industry collaboration from the ARLG in the form of advice, guidance, protocol design for drug, device, or diagnostic development. The ARLG develops, designs, implements, and manages a clinical research agenda to increase knowledge of antibacterial resistance (AR). The ARLG aims to advance research by building transformational trials that will change clinical practice and reduce the impact of antibacterial resistance and antimicrobial resistance through the following strategies: - Early clinical evaluation of new antibacterials; - Comparative effectiveness or efficacy trials; - Strategy trials to optimize currently licensed antibacterials (dose, duration, need for drug) to reduce the risk of resistance; - Clinical algorithm testing strategies; - Treatment-based prevention measures; - Diagnostics testing in the context of treatment trials, epidemiologic elements, or behavioral modification; - Effective infection control programs which include surveillance for resistant organisms, outbreak investigation, and antibiotic stewardship to prevent the development and spread of resistant organisms; - Novel facilities level activities to prevent the development of resistance.

In 1974, the US National Research Act was signed into law, there-by creating the National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research. One of the charges to the Commission was to identify the basic ethical principles that should underlie the conduct of biomedical and behavioral research involving human subjects and to develop guidelines which should be followed to assure that such research is conducted in accordance with those principles. In carrying out the above, the Commission was directed to consider: (i) the boundaries between biomedical and behavioral research and the accepted and routine practice of medicine, (ii) the role of assessment of risk-benefit criteria in the determination of the appropriateness of research involving human subjects, (iii) appropriate guidelines for the selection of human subjects for participation in such research and (iv) the nature and definition of informed consent in various research settings. The Belmont Report attempts to summarize the basic ethical principles identified by the Commission in the course of its deliberations.

This Crash Course video, The Deadliest Infectious Disease of All Time, explores the history, biology, and global impact of TB. From its ancient origins to its ongoing role as a leading cause of infectious death worldwide, the video examines how TB spreads, why it remains so deadly, and how social and political factors shape its burden. Engaging and informative, the episode highlights both scientific advances and enduring health inequities.

The 2025 Results Report is a snapshot of the partnerships' progress in the fight to end AIDS, TB and malaria during 2024.

The Global Health Network aims to strengthen health research in underserved areas by: Supporting and streamlining research where evidence is lacking. Promoting equity in participation and access to research benefits through open sharing of knowledge and data. Building sustainable, skilled research teams in low-resource settings capable of leading and competing globally.

New course - free and online - An Introduction and Practical Guide to Community Engagement and Involvement in Global Health Research

Good Clinical Laboratory Practice (GCLP) is a set of guidelines describing the application of those Good Laboratory Practice principles that are relevant to the analyses of samples from clinical trials while ensuring the purpose and objectives of the Good Clinical Practice principles are maintained. In so doing, the reliability, quality, consistency and integrity of data generated by clinical trial laboratories can be assure which is crucial to the outcome of any clinical trial.

This ICH E6 GCP Investigator Site Training, in multiple languages, meets the Minimum Criteria for ICH GCP Investigator Site Personnel Training identified by TransCelerate BioPharma as necessary to enable mutual recognition of GCP training among trial sponsors.

New course - free and online - Research Ethics Online Training (V2)

The templates have been shared by groups, and are free to use and adapt for individual's research studies.

Our research team is accepting applications for a postdoctoral fellowship based in the Department of Epidemiology at the Johns Hopkins Bloomberg School of Public Health under the mentorship of Dr. David Dowdy and Dr. Emily Kendall. The start date for these fellowships is flexible, but preference will be given to applicants who can start by June 2026. According to JHU policy, appointments will be for one year, renewable by mutual agreement – our hope is to recruit a fellow who is interested in a two-year fellowship. We are seeking fellows with a background in mathematical modeling and cost-effectiveness analysis, and interest in combining these tools with both primary and secondary data sources to answer policy-relevant questions about tuberculosis interventions. Reflecting our team-based, collaborative approach to research, fellows will work with a broader mentorship team, with additional mentors drawn from the Center for Tuberculosis Research and other collaborating teams as appropriate. This fellowship will be funded from a combination of four specific projects (described below), providing flexibility to structure the fellowship around the goals of individual applicants. Successful fellows will help broaden our team’s horizons, enabling us to build new collaborations and explore new research areas. The specific deliverables for this fellowship are linked to ongoing field-based studies with empiric data collection, including: . Models of the impact and cost-effectiveness of school-based screening and prevention in India. Estimating the long-term impact and cost-effectiveness of school-based TB disease screening, with or without the addition of preventive therapy for people with infection . Models of the impact and cost-effectiveness of venue-targeted vaccination programs in Zambia, Nigeria, and Indonesia. Evaluating whether vaccination is more efficient when delivered at specific venues (e.g., prisons, mines, bars) than to the general population or at health facilities . Models of the impact and cost-effectiveness of novel diagnostic assays for tuberculosis. Understanding the importance of different design characteristics and implementation strategies for novel diagnostics, particularly those intended for children, screening, and/or drug susceptibility testing . Models of the impact and cost-effectiveness of drug susceptibility testing for bedaquiline. Forecasting the future and health impact of bedaquiline-resistant TB under different scenarios of availability and scale-up of drug susceptibility testing in key countries Applicants must have: . A recent PhD (or MD) degree in a relevant discipline (expected graduation in Spring 2026 is acceptable). . Strong quantitative background, with demonstrated ability to program in one or more scientific programming languages, e.g. R, Python, C++, etc. . Demonstrated ability to lead modeling research, as well as strong communication and writing skills. . Ability to work independently, function as part of a highly collaborative, interdisciplinary, open-source-oriented team, and contribute to biweekly team meetings and journal clubs. Application Procedures Interested applicants should submit the following via a single email to Dr. Dowdy (ddowdy1@jhmi.edu): - Cover letter describing research interests, career goals, and prior experience - Curriculum vitae - Contact information of 3 references (to be contacted only after first discussing with the applicant) Applications submitted by January 31 will be given priority. Initial interviews will be held in Feb 2025 and selections made promptly. We encourage applications regardless of precise timeline or current location, and we will work with qualified candidates to sort out hiring details and timelines. Please contact Dr. Dowdy and/or Dr. Kendall (ekendall@jhmi.edu) by email with any questions.

DEADLINE: January 2026 SEPTRE (SPIRIT Electronic Protocol Tool and Resource) is an innovative, web-based software solution that makes it easier to create, manage, and register high-quality protocols for clinical trials. From now until January 2026, The Global Health Network and EDCTP have a limited number of free individual three-year SEPTRE licenses for researchers based in low-resource settings.

The TBPod is a podcast for clinicians and policymakers caring for patients with tuberculosis. The podcasts present discussions with expert clinicians, researchers, policymakers and advocates about their work in the field of tuberculosis. These podcasts aim to engage and update those who are interested in the field of tuberculosis through discussions with leaders in the field of tuberculosis.

Late-breaker abstract submissions are open from 16 June 2026 to 22 July 2026. The Union World Conference on Lung Health is pleased to announce the late-breaker session related to lung health and tuberculosis (including extrapulmonary tuberculosis and post-tuberculosis sequelae). This late-breaker session includes all aspects of lung health and tuberculosis prevention, diagnosis, and treatment research (including basic and clinical science, epidemiology, social, behavioural, and health care delivery). In keeping with the spirit of a late-breaker session, we ask that only new, innovative and significant findings of broad interest that have occurred after 13 April, or for which information has just become available, be submitted for the late-breaker sessions.

Abstract, Travel Grant, and Challenging Case Submissions Now Open Deadline for Submissions: 21 September 2026 February 24 – 28, 2027 | Vancouver, BC, Canada The 2027 End TB Conference of the Union North American Region is looking forward to holding its 31st annual conference at the Sheraton Vancouver Wall Centre Hotel, 1000 Burrard St, Vancouver, BC, Canada, from February 24-27, 2027. We hope that you will join us in person to participate in our pre-conference postgraduate sessions and stay to attend our full conference. Please visit our website for ongoing conference program updates as we finalize our agenda over the next few months. We look forward to seeing to both new and familiar faces in support of the North American TB community.

The "Atlas of TB Innovations" is catalogue of all innovations in the fight against Tuberculosis (TB). Innovations showcases cutting-edge solutions, breakthrough technologies and transformative ideas that drive progress. Explore advancements shaping the future across various industries.

The PHA Editors will consider any manuscript reporting original research on progress to achieving the SDGs. Suitable topics include infection-related topics such as vaccines, infection prevention control, outbreaks and antimicrobial resistance. Non-communicable diseases of public health importance include nutrition, the impact of climate change and planetary health. The journal aims to improve public health practice and we welcome operational research, lessons from implementation and evaluations of public health interventions. We will also consider submissions that focus on issues related to health care access and universal health coverage, quality, efficiency, cost-effectiveness, ethics and equity as well as education and training.

In-person courses and virtual options, too - Free online courses We currently offer the following online courses, free of charge: How to develop a research grant proposal (English) Interpretation of CXR in children with presumptive TB (English) Interpretation of CXR in adults (French) Prevent TB: management of TB infection (English, French and Spanish)